This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | ICD-10: D32 | D32.0 Benign neoplasm of cerebral meninges | D32.1 Benign neoplasm of spinal meninges | D32.9 Benign neoplasm of meninges, unspecified | Special Copayment Reduction V193 (5% copayment, for 5 years from the registration date) |
| B. Synonyms | Meningioma, WHO grade 1 meningioma, benign neoplasm of the meninges, spinal meningioma, skull base meningioma, falx meningioma, parasagittal meningioma, olfactory groove meningioma, cavernous sinus meningioma, tuberculum sellae meningioma |
| C. Adult onset | Not low — most common in the 40s–70s; peak age of onset in the 60s; 2-3 times more common in women than men; rare in children but possible (presenting with raised intracranial pressure) |
| Contents | 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References |
| 1. History summary | Cushing and Eisenhardt (1938) established the meningioma classification system; the Simpson grade (1957) set the criteria for extent of resection; latest update with the WHO 2021 integrated molecular classification. |
| 2. Causes summary | Ionizing radiation (the only established risk factor); NF2 (neurofibromatosis type 2); female hormones (cause of female predominance); head trauma (controversial); association with mobile phones not proven. |
| 3. Genetics summary | NF2/TERT/CDKN2A (grades 2-3); AKT1 E17K, SMO, KLF4, TRAF7 (grade 1 skull base type); WHO 2021 integrated molecular grading; SMARCE1 (clear cell type). |
| 4. Epidemiology summary | About 36% of all primary brain tumors; female:male = 2-3:1; about 3,500-4,000 meningiomas per year in Korea; increase in asymptomatic incidental findings with the spread of MRI. |
| 5. Pathophysiology summary | NF2 loss → absence of merlin → loss of contact inhibition → proliferation of arachnoid cap cells; skull base meningiomas proceed via the AKT1/SMO pathways. |
| 6. Symptoms summary | Headache, seizures, focal neurological deficits, visual changes (varying with location); many found incidentally without symptoms; symptoms worsen rapidly when accompanied by cerebral edema. |
| 7. Signs summary | Enhancing dura-based mass on MRI + "dural tail" sign; calcification on CT; cerebral edema; surgical assessment by Simpson grade. |
| 8. Screening summary | No population screening; annual brain MRI in patients with confirmed NF2; increasing incidental findings with the spread of MRI. |
| 9. Diagnosis summary | Contrast-enhanced MRI (gadolinium); CT; MR spectroscopy; surgical biopsy; WHO 2021 CNS classification; molecular analysis of NF2, TERT and CDKN2A; Ki-67. |
| 10. Treatment summary | Surgery (Simpson grade 1-2 resection); stereotactic radiosurgery (SRS/GKRS); observation of small asymptomatic tumors; bevacizumab and everolimus for recurrent disease; proton therapy. |
| 11. Prognosis summary | WHO grade 1: 5-year recurrence 7-25% (depending on Simpson grade); WHO grade 2: 40-50% recurrence; overall 5-year survival over 90% for grade 1; location is decisive for prognosis. |
| 12. Prevention summary | Minimizing unnecessary head CT radiation exposure (children); genetic counseling for NF2 families; association with mobile phones not proven; regular MRI (NF2 patients). |
The history of meningioma goes hand in hand with the history of neurosurgery. Descriptions of intracranial tumors go back to antiquity, but the modern understanding of meningioma began in the 19th century. In 1614, Felix Platter first described an intracranial extracerebral tumor, and several surgeons subsequently attempted resection of intracranial meningeal-based tumors. In 1887, the British neurosurgeon William Macewen reported the successful resection of a meningioma.
The most important milestone in the history of meningioma was the publication in 1938 of the monumental book co-authored by Harvey Cushing and Louise Eisenhardt, Meningiomas: Their Classification, Regional Behaviour, Life History, and Surgical End Results. This book systematically described the histological subtypes of meningioma, location-specific features and surgical results, laying the foundation of modern meningioma pathology and surgery. Cushing described the high-grade meningioma subtypes of the time as a "subgroup of low malignancy."
In 1957, Donald Simpson published the Simpson grading scale, classifying the extent of surgical resection of meningioma into grades I-V; by quantifying the relationship between extent of resection and recurrence rate, this system became the benchmark for meningioma surgery. The WHO began publishing its classification of brain tumors in 1979, and the classification system evolved through 2000 (3rd edition), 2007 (4th edition), 2016 (revised 4th edition) and 2021 (5th edition). The 2021 WHO classification was revised to integrate molecular genetic information with histological features so that meningiomas are graded more accurately.
Ionizing radiation is the only established environmental risk factor for meningioma. Many studies have consistently confirmed an increased risk of meningioma with head and neck radiation therapy (especially at a young age), repeated dental X-ray exposure and among survivors of atomic bomb exposure (Hiroshima, Nagasaki). Radiation-associated meningiomas have a long latency (mean 35-40 years) and tend to be multiple and to show more aggressive histological features. Neurofibromatosis type 2 (NF2): in carriers of germline NF2 mutations, meningiomas develop together with bilateral acoustic neuromas (vestibular schwannomas), and this is the most firmly established risk factor among single-gene syndromes. Female hormones: the female predominance of meningioma (female:male = 2-3:1) is associated with estrogen and progesterone receptor expression, and accelerated growth during pregnancy and the association with breast cancer suggest hormone dependence. However, a causal relationship between oral contraceptives and meningioma has not yet been established. Head trauma: an association with the development of meningioma has been reported in some studies, but a causal relationship has not been clearly proven. Mobile phone use: large epidemiological studies such as the INTERPHONE study have not proven an association with meningioma.
Through the 2021 WHO classification, the genetics of meningioma has been integrated with histological grade and molecular features. Molecular subtypes of WHO grade 1 meningioma: NF2-nonmutant (skull base) meningiomas are characterized by AKT1 E17K mutations (meningothelial type), SMO mutations (meningothelial type, anterior skull base), KLF4 K409Q mutations (secretory type) and TRAF7 mutations (coexisting with several subtypes). These mutations are largely mutually exclusive with NF2 mutations. NF2-mutant meningiomas occur mainly over the hemispheric convexity, falx and spinal cord and are accompanied by 22q deletion. WHO grade 2-3 meningiomas: TERT promoter mutations (C228T, C250T), CDKN2A/B deletion, and 1p, 14q and 18q deletions are associated with higher grade and have been incorporated into the 2021 WHO classification as criteria for upgrading. SMARCE1 mutations are specific to the clear cell type (clear cell meningioma, mainly spinal and cerebellopontine angle). BAP1 mutations are associated with the rhabdoid type.
Meningioma is the most common primary brain tumor. According to US CBTRUS data, meningiomas account for about 36% of all primary brain and spinal cord tumors. The annual incidence is about 7-8 per 100,000 population (US), and about 3,500-4,000 new cases are diagnosed each year in Korea. It is 2-3 times more common in women than in men, and its frequency increases with age, peaking in the 60s–70s.
With the spread of MRI, incidental meningiomas have increased markedly. Autopsy studies estimate the prevalence of meningioma at about 2%, meaning that many meningiomas remain asymptomatic and undiagnosed during life. WHO grade 1 (benign) accounts for about 80-85%, WHO grade 2 (atypical) for about 15-18% and WHO grade 3 (malignant) for about 1-2%. Spinal meningiomas (D32.1) account for about 10% of all meningiomas and are more common in women.
Meningiomas originate from arachnoid cap cells. These cells are constituents of the arachnoid, one of the meninges surrounding the brain and spinal cord, and normally cell growth and death are in balance. Loss of the merlin protein due to NF2 gene mutation (22q12.2) is the most common mechanism. Merlin is a tumor suppressor protein of the ERM (Ezrin-Radixin-Moesin) protein family that suppresses cell proliferation by transmitting cell-cell contact inhibition signals. When contact inhibition disappears with merlin loss, arachnoid cells proliferate without limit, forming a meningioma.
The AKT1 E17K mutation, common in skull base meningiomas, constitutively activates the PI3K/AKT pathway, promoting cell survival and proliferation. SMO mutations (Hedgehog pathway) and TRAF7 mutations (regulation of the NF-κB pathway) also each contribute to the development of meningiomas of distinct histological types. Radiation-associated meningiomas follow a pathway in which incomplete repair after radiation-induced DNA double-strand breaks leads to NF2 loss and chromosomal abnormalities. Expression of estrogen and progesterone receptors influences meningioma cell growth, which is the cause of accelerated meningioma growth during pregnancy.
Symptoms of meningioma (D32) vary widely depending on tumor location, size, growth rate and the degree of compression of surrounding brain structures. Many meningiomas, especially small tumors, are asymptomatic and found incidentally on head imaging. Headache: the most common nonspecific symptom. It occurs regardless of tumor location, and headache that is worse in the morning and progressively worsens suggests raised intracranial pressure. Seizures: occur in cerebral convexity meningiomas due to irritation of the adjacent cerebral cortex and may present as focal seizures or secondarily generalized seizures. Seizures are the first symptom of meningioma in about 30% of cases. Focal neurological deficits: depending on tumor location, hemiparesis, sensory abnormalities, speech disorders, gait abnormalities, cognitive decline and personality changes occur. Visual changes: in tuberculum sellae meningioma and olfactory groove meningioma, compression of the optic nerve can cause decreased visual acuity and visual field defects. Spinal meningioma (D32.1): presents with progressive limb weakness, sensory abnormalities and bladder and bowel dysfunction.
MRI (magnetic resonance imaging) findings are central to the diagnosis of meningioma. On gadolinium-enhanced MRI, a well-circumscribed, homogeneous, strongly enhancing mass based on the dura mater is characteristic. Dural tail sign: on contrast-enhanced MRI, a linear finding of thickened, enhancing dura at the junction of the tumor and dura is specific to meningioma but can also appear in other dural tumors. Peritumoral edema may be present, and the degree of edema correlates with symptom severity. CT findings: a hyperdense dura-based mass, often with calcification. Hyperostosis of the adjacent skull is a characteristic finding of meningioma. MR spectroscopy: an alanine peak is specifically observed in meningioma. Intraoperative assessment by Simpson grade: classifies the extent of resection from grade I (complete resection including the dura and hyperostotic skull) to grade V (simple decompression).
Population screening for meningioma is currently not recommended. However, regular imaging surveillance is recommended for the following high-risk groups. Neurofibromatosis type 2 (NF2): in patients with confirmed NF2, meningiomas and other NF2-related tumors (bilateral acoustic neuromas, spinal tumors) are monitored with annual brain and spinal MRI. Meningiomas develop in 50% of NF2 patients. History of head and neck radiation therapy: long-term follow-up head MRI is recommended for patients who received cranial radiation therapy in childhood (treatment of Hodgkin lymphoma, pediatric brain tumors). Because the latency of radiation-associated meningiomas is decades long, surveillance must continue into adulthood. Incidentally found small meningiomas: for asymptomatic small meningiomas (3cm or less) found incidentally on MRI, MRI is repeated after 6 months to check the growth rate, and if stable, follow-up is at 1-2-year intervals. With advances in MRI technology, asymptomatic meningiomas are frequently found when head MRI is performed.
The diagnosis of meningioma is mostly made clinically through contrast-enhanced MRI, and when typical imaging findings are present, a clinical diagnosis is possible without tissue biopsy. Definitive diagnosis and grading are made by histopathological examination via surgical resection or biopsy. Grading of meningioma under the WHO 2021 classification of CNS tumors: histological features (mitotic index, brain invasion, specific histological subtypes) + molecular features (TERT promoter mutation, CDKN2A/B deletion, NF2 mutation, etc.) are integrated to assign WHO grade 1, 2 or 3. Ki-67 (MIB-1) index: an index of cell proliferative activity, low in grade 1 (under 3%), 5-10% in grade 2, and rising to 20% or more in grade 3. Functional MRI studies: MR spectroscopy and perfusion MRI (ASL, DSC) are used adjunctively to predict tumor grade. Angiography: used for planning preoperative embolization in highly vascular meningiomas.
Treatment of meningioma (D32) is individualized according to tumor location, size, growth rate, patient age and general condition, and the presence of symptoms. Watchful waiting: for asymptomatic small meningiomas (3cm or less) and elderly patients at high surgical risk, MRI follow-up is performed at 6-month to 1-year intervals. When the annual growth rate is low (<2mm/year), long-term observation is appropriate. Surgery (craniotomy): for symptomatic or growing meningiomas, Simpson grade 1-2 resection is the goal. The recurrence rate is lowest after Simpson grade 1 resection (complete resection including the dura and hyperostotic skull). Complete resection of skull base meningiomas is difficult, so balancing functional preservation according to anatomical location with tumor control is important. Stereotactic radiosurgery (SRS): Gamma Knife, CyberKnife and linear accelerator (LINAC) SRS are effective for small (3cm or less) meningiomas or residual tumor after surgery. The 5-year control rate of SRS for WHO grade 1 meningioma is about 85-95%. Fractionated stereotactic radiotherapy (FSRT): used in sites where a single high-dose fraction is risky, such as near the optic nerve. Systemic therapy: bevacizumab, everolimus and hydroxyurea have been studied in recurrent WHO grade 2-3 meningiomas, but their efficacy is limited. Proton therapy is advantageous for radiation therapy of skull base meningiomas.
The prognosis of meningioma (D32) varies greatly with WHO grade, Simpson resection grade and location. WHO grade 1 (benign) meningioma: 5-year recurrence about 7-10% and 10-year about 20-25% after Simpson grade 1 resection. 5-year recurrence about 17-25% after Simpson grade 2 resection. Overall 5-year survival is very good, at over 90%. WHO grade 2 (atypical) meningioma: 5-year recurrence about 40-50%. Overall 5-year survival about 70-80%. Postoperative radiation therapy is recommended to prevent recurrence. WHO grade 3 (anaplastic/malignant) meningioma: recurrence over 50%, 5-year survival about 50%. Location is important for prognosis: skull base meningiomas are difficult to resect completely and recur frequently. Brain invasion is an independent risk factor for recurrence, and its importance is emphasized in the WHO 2021 classification. Follow-up after treatment: WHO grade 1: MRI at 1 year after surgery, then every 2-3 years. WHO grade 2-3: MRI every 6 months.
Minimizing unnecessary head radiation exposure: ionizing radiation exposure such as head and neck CT and dental X-rays should be performed only when truly necessary, and head CT should be minimized especially in children and adolescents. Caution is needed because some studies have reported linking dental radiation exposure with meningioma risk. NF2 genetic counseling and regular surveillance: in patients diagnosed as carriers of germline NF2 mutations, genetic counseling is provided along with annual brain and spinal MRI to detect NF2-related tumors, including meningiomas, early. Genetic testing is considered when a family member has NF2. Regarding mobile phone use: to date, large studies have not proven an association with meningioma risk, so excessive anxiety is unnecessary. As a precaution, however, use of earphones is recommended. Optimizing radiation therapy: in head and neck radiation therapy, intensity-modulated radiation therapy (IMRT) and proton therapy techniques that minimize the field and dose of radiation exposure are used.